{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:30Z","timestamp":1791389010220,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","annalspathology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.anndiagpath.2015.12.002","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T20:00:07Z","timestamp":1450468807000},"page":"7-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications"],"prefix":"10.1016","volume":"21","author":[{"given":"Boaz","family":"Kurtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Ojaimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongming","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Fallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-8939","authenticated-orcid":false,"given":"Minghao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.anndiagpath.2015.12.002_bb0005","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"6122","key":"10.1016\/j.anndiagpath.2015.12.002_bb0010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"issue":"6122","key":"10.1016\/j.anndiagpath.2015.12.002_bb0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.anndiagpath.2015.12.002_bb0020","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1073\/pnas.1303607110","article-title":"TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal","volume":"110","author":"Killela","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anndiagpath.2015.12.002_bb0025","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1038\/ncomms3185","article-title":"Frequency of TERT promoter mutations in human cancers","volume":"4","author":"Vinagre","year":"2013","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.anndiagpath.2015.12.002_bb0030","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2015.12.002_bb0035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.anndiagpath.2015.12.002_bb0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.ctrv.2011.10.004","article-title":"Recommendations for the optimal management of early and advanced urothelial carcinoma","volume":"38","author":"Castellano","year":"2012","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.anndiagpath.2015.12.002_bb0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S0094-0143(21)00225-1","article-title":"Endoscopic applications of laser energy","volume":"13","author":"Smith","year":"1986","journal-title":"Urol Clin North Am"},{"issue":"5","key":"10.1016\/j.anndiagpath.2015.12.002_bb0050","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/S0022-5347(05)68208-0","article-title":"Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association","volume":"162","author":"Smith","year":"1999","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2015.12.002_bb0055","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3810\/pgm.2011.05.2283","article-title":"Diagnosis and management of urothelial carcinoma of the bladder","volume":"123","author":"Tanaka","year":"2011","journal-title":"Postgrad Med"},{"issue":"1","key":"10.1016\/j.anndiagpath.2015.12.002_bb0060","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrurol.2011.193","article-title":"Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?","volume":"9","author":"Netto","year":"2012","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2015.12.002_bb0065","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eururo.2013.08.057","article-title":"Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine","volume":"65","author":"Hurst","year":"2014","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.anndiagpath.2015.12.002_bb0070","doi-asserted-by":"crossref","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","article-title":"TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine","volume":"73","author":"Kinde","year":"2013","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.anndiagpath.2015.12.002_bb0075","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.4161\/cc.24662","article-title":"Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma","volume":"12","author":"Liu","year":"2013","journal-title":"Cell Cycle"},{"issue":"8","key":"10.1016\/j.anndiagpath.2015.12.002_bb0080","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ejca.2015.03.010","article-title":"Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation","volume":"51","author":"Huang","year":"2015","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.anndiagpath.2015.12.002_bb0085","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/ijc.29526","article-title":"Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer","volume":"137","author":"Hosen","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.anndiagpath.2015.12.002_bb0090","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/14737159.8.1.63","article-title":"Biological markers in the diagnosis of recurrent bladder cancer: an overview","volume":"8","author":"Mohammed","year":"2008","journal-title":"Expert Rev Mol Diagn"},{"issue":"11","key":"10.1016\/j.anndiagpath.2015.12.002_bb0095","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/dc.21769","article-title":"Urine cytopathology: challenges, pitfalls, and mimics","volume":"40","author":"Thiryayi","year":"2012","journal-title":"Diagn Cytopathol"},{"issue":"Suppl. 2","key":"10.1016\/j.anndiagpath.2015.12.002_bb0100","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1038\/modpathol.2008.193","article-title":"Diagnosis of urothelial carcinoma from urine","volume":"22","author":"Tetu","year":"2009","journal-title":"Mod Pathol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2015.12.002_bb0105","first-page":"6682","article-title":"The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation","volume":"20","author":"Garfield","year":"2013","journal-title":"Can J Urol"},{"issue":"15","key":"10.1016\/j.anndiagpath.2015.12.002_bb0115","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1002\/cncr.25227","article-title":"The excessive cost of early stage bladder cancer care: are providers really to blame?","volume":"116","author":"Hemani","year":"2010","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.anndiagpath.2015.12.002_bb0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.urolonc.2013.06.001","article-title":"Urine markers for detection and surveillance of bladder cancer","volume":"32","author":"Xylinas","year":"2014","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.anndiagpath.2015.12.002_bb0125","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0022-5347(05)63991-2","article-title":"Fibroblast growth factors and their receptors in transitional cell carcinoma","volume":"169","author":"Munro","year":"2003","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2015.12.002_bb0130","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1053\/j.semdp.2013.11.005","article-title":"Molecular genetics and genomics progress in urothelial bladder cancer","volume":"30","author":"Netto","year":"2013","journal-title":"Semin Diagn Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2015.12.002_bb0135","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAS.0000000000000305","article-title":"Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation","volume":"39","author":"Zhong","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2015.12.002_bb0140","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-014-0047-7","article-title":"High frequency of TERT promoter mutation in small cell carcinoma of bladder, but not in small cell carcinoma of other origins","volume":"7","author":"Zheng","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.anndiagpath.2015.12.002_bb0145","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.18632\/oncotarget.1829","article-title":"TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas","volume":"5","author":"Wang","year":"2014","journal-title":"Oncotarget"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913415001525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913415001525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T21:25:16Z","timestamp":1653859516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913415001525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":28,"alternative-id":["S1092913415001525"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.12.002","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}